There's lots that can go wrong with any drug launch. The wreckage is considerable for dev-stage biotechs trying to transition into operating companies (really ANY company trying to make that transition). I just don't happen to believe manufacturing problems will be an issue for Provenge.
The blogger is clearly short, but that doesn’t mean everything in the blog ought to be dismissed outright. For instance, the blogger’s point about DNDN’s giving out sales projections before approval has some merit, IMO.
News 
Market Data 
Discover 
